Crown laboratories completes acquisition of revance therapeutics

New york--(business wire)--yesterday, crown laboratories, inc. ("crown"), a hildred capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of revance therapeutics, inc. ("revance") (nasdaq: rvnc), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. jeff bedard, founder and chief executive officer of crown commented, “we are excited to offici.
CCK Ratings Summary
CCK Quant Ranking